David Reardon, MD | Authors

July 24, 2020

David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.

February 10, 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.

January 29, 2016

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses identifying certain characteristics in a patient's brain tumor in order to administer better treatment.

November 20, 2015

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.

June 02, 2015

November 17, 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.